Patents by Inventor James Lindsay Carr
James Lindsay Carr has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230391725Abstract: The present invention relates to compounds of formula (I) or pharmaceutically acceptable salts, solvates, hydrates, tautomers or stereoisomers thereof, wherein R1, R2, R2a, R3, R4, R4a, R4b, R4c, R4d, R4e, R4f, R5, R6 have the meaning as indicated in the description and claims The invention further relates to pharmaceutical compositions comprising said compounds, their use as medicament and in a method for treating or preventing of one or more diseases or disorders associated with integrated stress response.Type: ApplicationFiled: October 21, 2021Publication date: December 7, 2023Applicant: Evotec International GmbHInventors: Holly Victoria Atton, Christopher John Brown, James Lindsay Carr, Gert-Jan Hofman, Mohamad Sabbah, Daryl Simon Walter
-
Publication number: 20230125481Abstract: The present invention relates to compounds of formula (I) or pharmaceutically acceptable salts, solvates, hydrates, tautomers or stereoisomers thereof, wherein R1, R2, R2a, R3, Ra1, Ra2, Ra4, Ra5, X1, X1a, A1 and A2 have the meaning as indicated in the description and claims. The invention further relates to pharmaceutical compositions comprising said compounds, their use as medicament and in a method for treating and preventing of one or more diseases or disorders associated with integrated stress response.Type: ApplicationFiled: January 26, 2021Publication date: April 27, 2023Inventors: Christopher John BROWN, James Lindsay CARR, Mohamad SABBAH, Jeffrey Michael SCHKERYANTZ, Daryl Simon WALTER
-
Publication number: 20230129907Abstract: The present invention relates to compounds of formula (I) or pharmaceutically acceptable salts, solvates, hydrates, tautomers or stereoisomers thereof, wherein R1, R2, R2a, R3, Ra1, Ra2, Ra3, Ra4, Ra5, Ra6, A1 and A2 have the meaning as indicated in the description and claims. The invention further relates to pharmaceutical compositions comprising said compounds, their use as medicament and in a method for treating and preventing of one or more diseases or disorders associated with integrated stress response.Type: ApplicationFiled: March 10, 2021Publication date: April 27, 2023Inventors: Holly Victoria ATTON, Christopher John BROWN, James Lindsay CARR, Scott Alexander SADLER, Jonathan Paul SHINE, Daryl Simon WALTER
-
Publication number: 20220227747Abstract: The present invention relates to compounds of formula (I) or pharmaceutically acceptable salts, solvates, hydrates, tautomers or stereoisomers thereof, wherein R1, R2, R2a, R3, Ra2, Ra4, Ra5, Ra6, Ra7, X1, X1a, A1 and A2 have the meaning as indicated in the description and claims. The invention further relates to pharmaceutical compositions comprising said compounds, their use as medicament and in a method for treating and preventing of one or more diseases or disorders associated with integrated stress response.Type: ApplicationFiled: April 22, 2020Publication date: July 21, 2022Inventors: Holly ATTON, Christopher John BROWN, James Lindsay CARR, Serge CONVERS-REIGNIER, Michael CORR, Marissa FLOWER, Christopher Francis PALMER, Irena REBOULE, Mohamad SABBAH, Scott SADLER, Jonathan SHINE, Daryl Simon WALTER
-
Patent number: 11319324Abstract: The present invention covers substituted. Pyrazolo-pyrrolo-pyrimidine-dione (PPPD) compounds of general formula (I): in which R1, R2 and R3 are as defined herein, methods of preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of neurogenic diseases, as a sole agent or in combination with other active ingredients.Type: GrantFiled: October 18, 2018Date of Patent: May 3, 2022Assignees: Bayer Aktiengesellschaft, Bayer Pharma AktiengesellschaftInventors: Marcus Koppitz, Holger Siebeneicher, Nico Bräuer, Elisabeth Pook, Andrea Rotgeri, Roland Neuhaus, Oliver Martin Fischer, Jens Nagel, Adam James Davenport, James Lindsay Carr, Robert James Townsend, Nina Connelly Ursinyova, Shelley Anne Parrott
-
Publication number: 20210317128Abstract: The present invention covers substituted. Pyrazolo-pyrrolo-pyrimidine-dione (PPPD) compounds of general formula (I): in which R1, R2 and R3 are as defined herein, methods of preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of neurogenic diseases, as a sole agent or in combination with other active ingredients.Type: ApplicationFiled: October 18, 2018Publication date: October 14, 2021Applicants: Bayer Aktiengesellschaft, Bayer Pharma AktiengesellschaftInventors: Marcus KOPPITZ, Holger SIEBENEICHER, Nico BRÄUER, Elisabeth POOK, Andrea ROTGERI, Roland NEUHAUS, Oliver Martin FISCHER, Jens NAGEL, Adam James DAVENPORT, James Lindsay CARR, Robert James TOWNSEND, Nina CONNELLY URSINYOVA, Shelley Anne PARROTT
-
Publication number: 20210317092Abstract: The present invention relates to tetrazole containing compounds of general formula (I) as described and defined herein, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease syndrome, condition, or symptoms, in particular related to chronic pain and inflammation, as a sole agent or in combination with other active ingredients.Type: ApplicationFiled: December 18, 2017Publication date: October 14, 2021Inventors: Stefan BÄEURLE, Adam James DAVENPORT, Christopher STIMSON, James Lindsay CARR, Christian Abingdon BUBERT, Frédéric Jacques MARLIN, Jens NAGEL, Nicole SCHMIDT, Andrea ROTGERI, Horst IRLBACHER
-
Patent number: 10428061Abstract: The present invention relates to compounds of formula I wherein R1, R2, R3, R4a, R4b, R4c, R4d, L, A, Q, W and HET are each as defined herein. The compounds of the present invention are inhibitors of autotaxin (ATX) enzyme activity. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions (e.g. fibrosis) in which ATX activity is implicated.Type: GrantFiled: October 25, 2018Date of Patent: October 1, 2019Assignee: Cancer Research Technology LimitedInventors: Francesca Blum, James Lindsay Carr, Pritom Shah, Maria Del Mar Jimenez Quesada, Irene Farre Gutierrez
-
Publication number: 20190062324Abstract: The present invention relates to compounds of formula I wherein R1, R2, R3, R4a, R4b, R4c, R4d, L, A, Q, W and HET are each as defined herein. The compounds of the present invention are inhibitors of autotaxin (ATX) enzyme activity. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions (e.g. fibrosis) in which ATX activity is implicated.Type: ApplicationFiled: October 25, 2018Publication date: February 28, 2019Inventors: Francesca Blum, James Lindsay Carr, Pritom Shah, Maria Del Mar Jimenez Quesada, Irene Farre Gutierrez
-
Patent number: 10138230Abstract: The present invention relates to compounds of formula (I): wherein R1, R2, R3, R4a, R4b, R4C, R4d, L, A, Q, W and HET are each as defined herein. The compounds of the present invention are inhibitors of autotaxin (ATX) enzyme activity. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions (e.g. fibrosis) in which ATX activity is implicated.Type: GrantFiled: February 4, 2016Date of Patent: November 27, 2018Assignee: Cancer Research Technology LimitedInventors: Francesca Blum, James Lindsay Carr, Pritom Shah, Maria Del Mar Jimenez Quesada, Irene Farre Gutierrez
-
Publication number: 20180022742Abstract: The present invention relates to compounds of formula (I): wherein R1, R2, R3, R4a, R4b, R4C, R4d, L, A, Q, W and HET are each as defined herein. The compounds of the present invention are inhibitors of autotaxin (ATX) enzyme activity. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions (e.g. fibrosis) in which ATX activity is implicated.Type: ApplicationFiled: February 4, 2016Publication date: January 25, 2018Applicant: CANCER RESEARCH TECHNOLOGY LIMITEDInventors: Francesca BLUM, James Lindsay CARR, Pritom SHAH, Maria DEL MAR JIMENEZ QUESADA, Irene FARRE GUTIERREZ
-
Publication number: 20090247519Abstract: The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain amino-ethyl-amino-aryl (AEAA) compounds which, inter alia, inhibit protein kinase D (PKD) (e.g., PKD1, PKD2, PKD3). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit PKD, and in the treatment of diseases and conditions that are mediated by PKD, that are ameliorated by the inhibition of PKD, etc., including proliferative conditions such as cancer, etc.Type: ApplicationFiled: April 26, 2007Publication date: October 1, 2009Inventors: Tony Michael Raynham, Timothy Robin Hammonds, Julia Helen Gilliatt, Mark David Charles, Gregoire Alexandre Pave, Caroline Heather Foxton, James Lindsay Carr, Neela Sumit Mistry